| Literature DB >> 23935244 |
Robert Grealy1, Mary White, Patrick Stordeur, Dermot Kelleher, Derek G Doherty, Ross McManus, Thomas Ryan.
Abstract
INTRODUCTION: Severe sepsis in humans may be related to an underlying profound immune suppressive state. We investigated the link between gene expression of immune regulatory cytokines and the range of illness severity in patients with infection and severe sepsis.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23935244 PMCID: PMC3713593 DOI: 10.1155/2013/164246
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Demographics of patients recruited to study. Values expressed as means and 95% confidence intervals.
| Severe sepsis (ICU) | Infection | Control | ||
|---|---|---|---|---|
| ICU admission | Day 7 ICU | |||
|
| 54 | 32 | 53 | 20 |
| Median age (yrs) | 71 (60–76) | 72 (61–79) | 71 (49–81) | 30 (27–33) |
| Gender | ||||
| Male | 23 (54%) | 16 (53%) | 33 (62%) | 8 (40%) |
| Female | 27 (46%) | 14 (47%) | 20 (38%) | 12 (30%) |
| Patient type | ||||
| Surgery | 23 | 20 | — | — |
| Medical | 31 | 12 | — | — |
| Bacteraemia | ||||
| Gram positive | 10 | — | 24 | — |
| Gram negative | 3 | — | 29 | — |
| APACHE II | 21 (19–22) | 18.4 (15.7–21.7) | — | — |
| SOFA | 12 (9.1–15) | 8.9 (6.9–10.7) | — | — |
| SAPS II | 52 (47–57) | 50 (42–58) | — | — |
| Septic shock | 42 (84%) | 15 (50%) | — | — |
| Respiratory infection | 23 (46%) | 6 (20%) | — | — |
| Abdominal infection | 14 (28%) | 16 (53%) | — | — |
| Other infection | 13 (26%) | 8 (27%) | — | — |
SOFA: sequential organ failure assessment score; SAPS II: simplified acute physiology score; APACHE: acute physiology and chronic health evaluation.
Figure 1Number of patients with severe sepsis: blood was drawn for study at ICU admission, at day 7 of ICU admission, or both.
Lymphocyte subsets in patients with severe sepsis and healthy controls. All values are median and interquartile range. Analysis is by Wilcoxon rank sum test.
| Controls | Sepsis |
| |
|---|---|---|---|
|
| 6 | 6 | |
| T lymphocytes | |||
| CD3+ CCR7+ CD45RA− (%) | 6 (1.3–12.9) | 4.2 (2.7–10) | ns |
| CD3+ CCR7low CD45RA− (%) | 23.5 (20–31.3) | 21 (17–28.8) | ns |
| CD3+ CCR7+ CD45RA+ (%) | 12.7 (4–24.6) | 7.6 (5.3–17) | ns |
| CD3+ CCR7− CD45RA+ (%) | 28.2 (6.6–43) | 18.1 (14.1–24) | ns |
| CD3+ CD127+ (%) | 55 (53–59) | 37 (26–43.6) | 0.004 |
| CD3+ CD127− (%) | 17.5 (14.2–21) | 18.7 (7.1–24.7) | ns |
| CD16+ CD56+ (%) | 8.3 (4.9–12.3) | 1.9 (1–14) | ns |
| Monocytes | |||
| CD14+ | 3.1 (2.8–3.2) | 1.5 (1.3–2.9) | ns |
| CD16+ | 1.6 (0.8–3.2) | 0.6 (0.4–1.2) | 0.06 |
| CD14+/16+ | 0.1 (0.1–0.2) | 0.2 (0.1–1) | ns |
Cytokine mRNA levels in patients with severe sepsis and controls. Values denote copy numbers expressed as log10 per 107 copy numbers β-actin. Values are expressed as medians and interquartile ranges. Analysis by Wilcoxon rank sum test between healthy controls, patients with mild sepsis and severe sepsis day 1.
| Cytokine | Control | Control versus infection | Infection | Infection versus sepsis at ICU admission | Severe sepsis ICU admission |
|---|---|---|---|---|---|
| INF | 3 | ns | 2.8 |
| 2.3 |
| 2.7–3.3 | 2.6–3.2 | 1.8–2.6 | |||
|
|
|
| |||
|
| |||||
| TNF | 4.5 |
| 4.9 |
| 4.5 |
| 4.3–4.9 | 4.5–5.5 | 4.3–5 | |||
|
|
|
| |||
|
| |||||
| IL2 | 2.8 |
| 2.3 |
| 2 |
| 2.5–3.1 | 2.2–2.6 | 1.6–2.2 | |||
|
|
|
| |||
|
| |||||
| IL7 | 3.8 | ns | 3.7 |
| 3.4 |
| 3.7–4.1 | 3.5–4 | 3.2–3.7 | |||
|
|
|
| |||
|
| |||||
| IL10 | 2.6 |
| 2.9 |
| 3.2 |
| 2.4–2.7 | 2.8–3.2 | 2.9–3.5 | |||
|
|
|
| |||
|
| |||||
| IL23 | 5.1 |
| 4.8 |
| 4.5 |
| 5.0–5.4 | 4.6–5.1 | 4.3–4.8 | |||
|
|
|
| |||
|
| |||||
| IL27 | 2.5 |
| 3 | ns | 3.1 |
| 2.3–2.7 | 2.8–3.3 | 2.7–3.4 | |||
|
|
|
| |||
Figure 2Probability of presence of sepsis in relation to cytokine mRNA index. Logistic regression analysis; model; n = 87, r 2 = 0.39, P < 0.0001.